Marker Therapeutics Net Worth

Marker Therapeutics Net Worth Breakdown

  MRKR
The net worth of Marker Therapeutics is the difference between its total assets and liabilities. Marker Therapeutics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Marker Therapeutics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Marker Therapeutics' net worth can be used as a measure of its financial health and stability which can help investors to decide if Marker Therapeutics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Marker Therapeutics stock.

Marker Therapeutics Net Worth Analysis

Marker Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Marker Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Marker Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Marker Therapeutics' net worth analysis. One common approach is to calculate Marker Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Marker Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Marker Therapeutics' net worth. This approach calculates the present value of Marker Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Marker Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Marker Therapeutics' net worth. This involves comparing Marker Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Marker Therapeutics' net worth relative to its peers.
To determine if Marker Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Marker Therapeutics' net worth research are outlined below:
Marker Therapeutics generated a negative expected return over the last 90 days
Marker Therapeutics has high historical volatility and very poor performance
Marker Therapeutics may become a speculative penny stock
Marker Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 3.31 M. Net Loss for the year was (14.05 M) with loss before overhead, payroll, taxes, and interest of (5.6 M).
Marker Therapeutics currently holds about 18.08 M in cash with (16.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22.
Marker Therapeutics has a frail financial position based on the latest SEC disclosures
Marker Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Marker Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Marker Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
27th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

Follow Marker Therapeutics' market capitalization trends

The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.17 M.

Project Marker Therapeutics' profitablity

The company has Profit Margin (PM) of (1.8) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.25) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.25.
When accessing Marker Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Marker Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Marker Therapeutics' profitability and make more informed investment decisions.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Marker Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Marker Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Marker Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Vera Juan over a week ago
Acquisition by Vera Juan of 50000 shares of Marker Therapeutics at 1.59 subject to Rule 16b-3
 
Nadia Agopyan over a month ago
Acquisition by Nadia Agopyan of 40000 shares of Marker Therapeutics at 3.29 subject to Rule 16b-3
 
New Enterprise Associates 16, L.p. over two months ago
Acquisition by New Enterprise Associates 16, L.p. of 554250 shares of Marker Therapeutics at 3.2 subject to Rule 16b-3
 
Kim Anthony H. over three months ago
Acquisition by Kim Anthony H. of 160000 shares of Marker Therapeutics at 0.46 subject to Rule 16b-3
 
Kim Anthony H. over three months ago
Acquisition by Kim Anthony H. of 160000 shares of Marker Therapeutics at 3.29 subject to Rule 16b-3
 
Eansor Norman David over three months ago
Acquisition by Eansor Norman David of 14285 shares of Marker Therapeutics at 17.5 subject to Rule 16b-3
 
Kim Anthony H. over three months ago
Acquisition by Kim Anthony H. of 150512 shares of Marker Therapeutics subject to Rule 16b-3
 
Wasserman Frederick Gerald over three months ago
Acquisition by Wasserman Frederick Gerald of 12658 shares of Marker Therapeutics subject to Rule 16b-3
 
Sandell Scott D over six months ago
Acquisition by Sandell Scott D of 5714285 shares of Marker Therapeutics at 1.75 subject to Rule 16b-3
 
Elms Steve over six months ago
Acquisition by Elms Steve of 8000 shares of Marker Therapeutics at 1.72 subject to Rule 16b-3
 
Hoang Peter L. over six months ago
Acquisition by Hoang Peter L. of 388800 shares of Marker Therapeutics at 2.12 subject to Rule 16b-3
 
Hoang Tsvetelina P over six months ago
Acquisition by Hoang Tsvetelina P of 33159 shares of Marker Therapeutics at 2.14 subject to Rule 16b-3
Marker Therapeutics time-series forecasting models is one of many Marker Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Marker Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Marker Therapeutics Earnings per Share Projection vs Actual

Marker Therapeutics Corporate Management

Gerald GarrettSenior OperationsProfile
Juan MDCOO, CoFounderProfile
Peter MBACEO PresProfile
Dr SrSenior VirologyProfile
Nadia AgopyanSenior AffairsProfile
Monic MDChief OfficerProfile

Additional Tools for Marker Stock Analysis

When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.